A monitoring board’s recommendation to stop the study for futility took Wall Street by surprise, removing one more ...
The struggling cell therapy developer is exploring strategic alternatives, which, among other characteristics, make it a ...
The deal hands Viatris two non-opioid pain treatments that booked nearly $700 million in 2025 but could soon lose patent ...
Children should have the freedom to focus on school, friendships, family, sports, birthdays, and simply growing up. Yet ...
The Nobel laureates “laid the foundation” for a new field of brain research, the award committee wrote. Elsewhere, Roche and ...
A former congressman will take over for prominent lobbyist Steve Ubl. Elsewhere, recent buyout deals paid dividends for Mirum and AbbVie.
The pharma giant cut its partnership after a cancer drug disappointed in testing. Elsewhere, Teva and Samsung Bioepis expanded a partnership and space biotech Varda brought in $251 million.
Despite having an allogeneic cell therapy prospect that’s ready for late-stage testing in lymphoma, Caribou couldn’t secure ...
The FDA previously hadn’t ever accepted an application of a drug like fenebrutinib in two major forms of MS. But safety ...
A Dutch court barred Merck from selling subcutaneous Keytruda in several European countries. Elsewhere, an Insmed executive ...
The better-than-expected results could make Epkinly the new “undisputed” treatment standard in newly diagnosed DLBCL, ...
The purchase expands GE HealthCare’s radiopharmaceutical capabilities, helping manufacture and distribute time-sensitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results